Review



mouse kidney cancer cell line renca  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC mouse kidney cancer cell line renca
    FIGURE 1 The oncolytic activity of Pseudorabies virus live attenuated vaccine(PRV‐LAV) against kidney cancer in vitro. (A) Cell morphology <t>of</t> <t>A498,</t> Caki‐1, 786‐0, and <t>Renca</t> cells 48 h postinfection with PRV‐LAV. Phase‐contrast micrographs were captured using a Thermo EVOS M7000. Scale bars, 100 μm. (B) Cell viability assays were performed on A498, Caki‐1, 786‐0, and Renca cells 72 h after exposure to PRV‐LAV. Data are presented as the mean ± s.d. values (n = 5). A t‐test was used to determine the significance of differences between the PRV‐LAV infection group and the Mock group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) The expression of PRV gB in the infected cells was detected by immunofluorescence assay. Graphs were captured by Leica DMI8. Scale bars, 250 μm. (D) The expression of PRV gB was analyzed by western blot analysis after cancer cells were infected with PRV‐LAV (MOI = 1) and cultured for 0, 12, 24, 36, and 48 h. GAPDH was used as a loading control. Virus titer in the culture supernatant of A498 (E), Caki‐1 (F), 786‐0 (G), and Renca (H) cells post‐PRV‐LAV infection. Data are presented as the mean ± s.d. values (n = 4). PRV‐LAV, Pseudorabies virus live attenuated vaccine.
    Mouse Kidney Cancer Cell Line Renca, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 542 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+kidney+cancer+cell+line+renca/Renca/pm38549430-29-8-19
    Average 96 stars, based on 542 article reviews
    mouse kidney cancer cell line renca - by Bioz Stars, 2026-08
    96/100 stars

    Images

    1) Product Images from "Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with PD-1 blockade."

    Article Title: Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with PD-1 blockade.

    Journal: Journal of medical virology

    doi: 10.1002/jmv.29568

    FIGURE 1 The oncolytic activity of Pseudorabies virus live attenuated vaccine(PRV‐LAV) against kidney cancer in vitro. (A) Cell morphology of A498, Caki‐1, 786‐0, and Renca cells 48 h postinfection with PRV‐LAV. Phase‐contrast micrographs were captured using a Thermo EVOS M7000. Scale bars, 100 μm. (B) Cell viability assays were performed on A498, Caki‐1, 786‐0, and Renca cells 72 h after exposure to PRV‐LAV. Data are presented as the mean ± s.d. values (n = 5). A t‐test was used to determine the significance of differences between the PRV‐LAV infection group and the Mock group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) The expression of PRV gB in the infected cells was detected by immunofluorescence assay. Graphs were captured by Leica DMI8. Scale bars, 250 μm. (D) The expression of PRV gB was analyzed by western blot analysis after cancer cells were infected with PRV‐LAV (MOI = 1) and cultured for 0, 12, 24, 36, and 48 h. GAPDH was used as a loading control. Virus titer in the culture supernatant of A498 (E), Caki‐1 (F), 786‐0 (G), and Renca (H) cells post‐PRV‐LAV infection. Data are presented as the mean ± s.d. values (n = 4). PRV‐LAV, Pseudorabies virus live attenuated vaccine.
    Figure Legend Snippet: FIGURE 1 The oncolytic activity of Pseudorabies virus live attenuated vaccine(PRV‐LAV) against kidney cancer in vitro. (A) Cell morphology of A498, Caki‐1, 786‐0, and Renca cells 48 h postinfection with PRV‐LAV. Phase‐contrast micrographs were captured using a Thermo EVOS M7000. Scale bars, 100 μm. (B) Cell viability assays were performed on A498, Caki‐1, 786‐0, and Renca cells 72 h after exposure to PRV‐LAV. Data are presented as the mean ± s.d. values (n = 5). A t‐test was used to determine the significance of differences between the PRV‐LAV infection group and the Mock group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) The expression of PRV gB in the infected cells was detected by immunofluorescence assay. Graphs were captured by Leica DMI8. Scale bars, 250 μm. (D) The expression of PRV gB was analyzed by western blot analysis after cancer cells were infected with PRV‐LAV (MOI = 1) and cultured for 0, 12, 24, 36, and 48 h. GAPDH was used as a loading control. Virus titer in the culture supernatant of A498 (E), Caki‐1 (F), 786‐0 (G), and Renca (H) cells post‐PRV‐LAV infection. Data are presented as the mean ± s.d. values (n = 4). PRV‐LAV, Pseudorabies virus live attenuated vaccine.

    Techniques Used: Activity Assay, Virus, In Vitro, Infection, Expressing, Immunofluorescence, Western Blot, Cell Culture, Control

    FIGURE 2 The safety and therapeutic activity of Pseudorabies virus live attenuated vaccine (PRV‐LAV) against kidney cancer in vivo. (A) Timeline of the experimental setup for the experiments in the BALB/c mouse model. Weight curve (B) and survival rate curve (C) of mice after intravenous injection of vehicle or PRV‐LAV (4 × 107 PFUs) into the tail vein. Data are presented as the mean ± s.d. values (n = 6). (D) Timeline of the experimental setup for the experiments in the BALB/c nude mouse model. (E) Tumor volume curves of mice bearing A498 tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally). Data are presented as the mean ± s.d. values (n = 6). (F) Timeline of the experimental setup for the experiments in the Renca syngeneic models. (G) Tumor volume curves of mice bearing Renca tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally) with an initial tumor volume of approximately 100mm3. Data are presented as the mean ± s.d. values (n = 5). (H) Timeline of the experimental setup for the experiments in the Renca syngeneic models. (I) Tumor volume curves of mice bearing Renca tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally) with an initial tumor volume of approximately 200 mm3. Data are presented as the mean ± s.d. values (n = 5). In (E, G, I), comparisons were performed by AUC analysis. Statistical analysis was performed by t‐test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. PRV‐LAV, Pseudorabies virus live attenuated vaccine.
    Figure Legend Snippet: FIGURE 2 The safety and therapeutic activity of Pseudorabies virus live attenuated vaccine (PRV‐LAV) against kidney cancer in vivo. (A) Timeline of the experimental setup for the experiments in the BALB/c mouse model. Weight curve (B) and survival rate curve (C) of mice after intravenous injection of vehicle or PRV‐LAV (4 × 107 PFUs) into the tail vein. Data are presented as the mean ± s.d. values (n = 6). (D) Timeline of the experimental setup for the experiments in the BALB/c nude mouse model. (E) Tumor volume curves of mice bearing A498 tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally). Data are presented as the mean ± s.d. values (n = 6). (F) Timeline of the experimental setup for the experiments in the Renca syngeneic models. (G) Tumor volume curves of mice bearing Renca tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally) with an initial tumor volume of approximately 100mm3. Data are presented as the mean ± s.d. values (n = 5). (H) Timeline of the experimental setup for the experiments in the Renca syngeneic models. (I) Tumor volume curves of mice bearing Renca tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally) with an initial tumor volume of approximately 200 mm3. Data are presented as the mean ± s.d. values (n = 5). In (E, G, I), comparisons were performed by AUC analysis. Statistical analysis was performed by t‐test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. PRV‐LAV, Pseudorabies virus live attenuated vaccine.

    Techniques Used: Activity Assay, Virus, In Vivo, Injection



    Similar Products

    mouse kidney cancer cell line renca  (ATCC)
    96
    ATCC mouse kidney cancer cell line renca
    FIGURE 1 The oncolytic activity of Pseudorabies virus live attenuated vaccine(PRV‐LAV) against kidney cancer in vitro. (A) Cell morphology <t>of</t> <t>A498,</t> Caki‐1, 786‐0, and <t>Renca</t> cells 48 h postinfection with PRV‐LAV. Phase‐contrast micrographs were captured using a Thermo EVOS M7000. Scale bars, 100 μm. (B) Cell viability assays were performed on A498, Caki‐1, 786‐0, and Renca cells 72 h after exposure to PRV‐LAV. Data are presented as the mean ± s.d. values (n = 5). A t‐test was used to determine the significance of differences between the PRV‐LAV infection group and the Mock group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) The expression of PRV gB in the infected cells was detected by immunofluorescence assay. Graphs were captured by Leica DMI8. Scale bars, 250 μm. (D) The expression of PRV gB was analyzed by western blot analysis after cancer cells were infected with PRV‐LAV (MOI = 1) and cultured for 0, 12, 24, 36, and 48 h. GAPDH was used as a loading control. Virus titer in the culture supernatant of A498 (E), Caki‐1 (F), 786‐0 (G), and Renca (H) cells post‐PRV‐LAV infection. Data are presented as the mean ± s.d. values (n = 4). PRV‐LAV, Pseudorabies virus live attenuated vaccine.
    Mouse Kidney Cancer Cell Line Renca, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+kidney+cancer+cell+line+renca/Renca/pm38549430-29-8-19
    Average 96 stars, based on 1 article reviews
    mouse kidney cancer cell line renca - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier
    renca mouse kidney cancer cell line  (ATCC)
    96
    ATCC renca mouse kidney cancer cell line
    FIGURE 1 The oncolytic activity of Pseudorabies virus live attenuated vaccine(PRV‐LAV) against kidney cancer in vitro. (A) Cell morphology <t>of</t> <t>A498,</t> Caki‐1, 786‐0, and <t>Renca</t> cells 48 h postinfection with PRV‐LAV. Phase‐contrast micrographs were captured using a Thermo EVOS M7000. Scale bars, 100 μm. (B) Cell viability assays were performed on A498, Caki‐1, 786‐0, and Renca cells 72 h after exposure to PRV‐LAV. Data are presented as the mean ± s.d. values (n = 5). A t‐test was used to determine the significance of differences between the PRV‐LAV infection group and the Mock group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) The expression of PRV gB in the infected cells was detected by immunofluorescence assay. Graphs were captured by Leica DMI8. Scale bars, 250 μm. (D) The expression of PRV gB was analyzed by western blot analysis after cancer cells were infected with PRV‐LAV (MOI = 1) and cultured for 0, 12, 24, 36, and 48 h. GAPDH was used as a loading control. Virus titer in the culture supernatant of A498 (E), Caki‐1 (F), 786‐0 (G), and Renca (H) cells post‐PRV‐LAV infection. Data are presented as the mean ± s.d. values (n = 4). PRV‐LAV, Pseudorabies virus live attenuated vaccine.
    Renca Mouse Kidney Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+kidney+cancer+cell+line+renca/Renca/pm37182514-66-0-9
    Average 96 stars, based on 1 article reviews
    renca mouse kidney cancer cell line - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 1 The oncolytic activity of Pseudorabies virus live attenuated vaccine(PRV‐LAV) against kidney cancer in vitro. (A) Cell morphology of A498, Caki‐1, 786‐0, and Renca cells 48 h postinfection with PRV‐LAV. Phase‐contrast micrographs were captured using a Thermo EVOS M7000. Scale bars, 100 μm. (B) Cell viability assays were performed on A498, Caki‐1, 786‐0, and Renca cells 72 h after exposure to PRV‐LAV. Data are presented as the mean ± s.d. values (n = 5). A t‐test was used to determine the significance of differences between the PRV‐LAV infection group and the Mock group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) The expression of PRV gB in the infected cells was detected by immunofluorescence assay. Graphs were captured by Leica DMI8. Scale bars, 250 μm. (D) The expression of PRV gB was analyzed by western blot analysis after cancer cells were infected with PRV‐LAV (MOI = 1) and cultured for 0, 12, 24, 36, and 48 h. GAPDH was used as a loading control. Virus titer in the culture supernatant of A498 (E), Caki‐1 (F), 786‐0 (G), and Renca (H) cells post‐PRV‐LAV infection. Data are presented as the mean ± s.d. values (n = 4). PRV‐LAV, Pseudorabies virus live attenuated vaccine.

    Journal: Journal of medical virology

    Article Title: Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with PD-1 blockade.

    doi: 10.1002/jmv.29568

    Figure Lengend Snippet: FIGURE 1 The oncolytic activity of Pseudorabies virus live attenuated vaccine(PRV‐LAV) against kidney cancer in vitro. (A) Cell morphology of A498, Caki‐1, 786‐0, and Renca cells 48 h postinfection with PRV‐LAV. Phase‐contrast micrographs were captured using a Thermo EVOS M7000. Scale bars, 100 μm. (B) Cell viability assays were performed on A498, Caki‐1, 786‐0, and Renca cells 72 h after exposure to PRV‐LAV. Data are presented as the mean ± s.d. values (n = 5). A t‐test was used to determine the significance of differences between the PRV‐LAV infection group and the Mock group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) The expression of PRV gB in the infected cells was detected by immunofluorescence assay. Graphs were captured by Leica DMI8. Scale bars, 250 μm. (D) The expression of PRV gB was analyzed by western blot analysis after cancer cells were infected with PRV‐LAV (MOI = 1) and cultured for 0, 12, 24, 36, and 48 h. GAPDH was used as a loading control. Virus titer in the culture supernatant of A498 (E), Caki‐1 (F), 786‐0 (G), and Renca (H) cells post‐PRV‐LAV infection. Data are presented as the mean ± s.d. values (n = 4). PRV‐LAV, Pseudorabies virus live attenuated vaccine.

    Article Snippet: Human kidney cancer cell line A498 (HTB‐44) and mouse kidney cancer cell line Renca (CRL‐2947) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Activity Assay, Virus, In Vitro, Infection, Expressing, Immunofluorescence, Western Blot, Cell Culture, Control

    FIGURE 2 The safety and therapeutic activity of Pseudorabies virus live attenuated vaccine (PRV‐LAV) against kidney cancer in vivo. (A) Timeline of the experimental setup for the experiments in the BALB/c mouse model. Weight curve (B) and survival rate curve (C) of mice after intravenous injection of vehicle or PRV‐LAV (4 × 107 PFUs) into the tail vein. Data are presented as the mean ± s.d. values (n = 6). (D) Timeline of the experimental setup for the experiments in the BALB/c nude mouse model. (E) Tumor volume curves of mice bearing A498 tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally). Data are presented as the mean ± s.d. values (n = 6). (F) Timeline of the experimental setup for the experiments in the Renca syngeneic models. (G) Tumor volume curves of mice bearing Renca tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally) with an initial tumor volume of approximately 100mm3. Data are presented as the mean ± s.d. values (n = 5). (H) Timeline of the experimental setup for the experiments in the Renca syngeneic models. (I) Tumor volume curves of mice bearing Renca tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally) with an initial tumor volume of approximately 200 mm3. Data are presented as the mean ± s.d. values (n = 5). In (E, G, I), comparisons were performed by AUC analysis. Statistical analysis was performed by t‐test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. PRV‐LAV, Pseudorabies virus live attenuated vaccine.

    Journal: Journal of medical virology

    Article Title: Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with PD-1 blockade.

    doi: 10.1002/jmv.29568

    Figure Lengend Snippet: FIGURE 2 The safety and therapeutic activity of Pseudorabies virus live attenuated vaccine (PRV‐LAV) against kidney cancer in vivo. (A) Timeline of the experimental setup for the experiments in the BALB/c mouse model. Weight curve (B) and survival rate curve (C) of mice after intravenous injection of vehicle or PRV‐LAV (4 × 107 PFUs) into the tail vein. Data are presented as the mean ± s.d. values (n = 6). (D) Timeline of the experimental setup for the experiments in the BALB/c nude mouse model. (E) Tumor volume curves of mice bearing A498 tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally). Data are presented as the mean ± s.d. values (n = 6). (F) Timeline of the experimental setup for the experiments in the Renca syngeneic models. (G) Tumor volume curves of mice bearing Renca tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally) with an initial tumor volume of approximately 100mm3. Data are presented as the mean ± s.d. values (n = 5). (H) Timeline of the experimental setup for the experiments in the Renca syngeneic models. (I) Tumor volume curves of mice bearing Renca tumors treated with vehicle or PRV‐LAV (1 × 107 PFUs, intratumorally) with an initial tumor volume of approximately 200 mm3. Data are presented as the mean ± s.d. values (n = 5). In (E, G, I), comparisons were performed by AUC analysis. Statistical analysis was performed by t‐test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. PRV‐LAV, Pseudorabies virus live attenuated vaccine.

    Article Snippet: Human kidney cancer cell line A498 (HTB‐44) and mouse kidney cancer cell line Renca (CRL‐2947) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Activity Assay, Virus, In Vivo, Injection